Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
A Phase II Trial of Epirubicin/Docetaxel in the First-Line Treatment of Patients With Metastatic Breast Cancer
Sponsor: Aventis Pharmaceuticals
Terminated
This trial was terminated. No reason was provided.
A PHASE2 clinical study on Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by Aventis Pharmaceuticals and has accumulated 7 data snapshots since 2001. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)Upon determination of eligibility, all patients will receive:
Docetaxel + Epirubicin
Both drugs will be repeated at 21-day intervals
Upon determination of eligibility, all patients will receive:
Docetaxel + Epirubicin
Both drugs will be repeated at 21-day intervals
Status Flow
Change History
7 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Sep 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aventis Pharmaceuticals
- Pharmacia and Upjohn
- SCRI Development Innovations, LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.